Results 1 to 10 of about 14,263 (70)

Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene

Revista Brasileira de Hematologia e Hemoterapia, 2013
We report here on a rare case of BCR-ABL1-negative atypical chronic myeloid leukemia with a t(9;22)(p24;q11.2)translocation and a BCR-JAK2 fusion gene, with resistance to the tyrosine kinase inhibitors imatinib and dasatinib.
Marcelo Bellesso, Rodrigo Santucci, Daniela Ferreira Dias, Renato Centrone, Renata Campos Elias   +4 more
doaj   +1 more source

Heterogeneous nuclear ribonucleoprotein K in cancer biology and its therapeutic applications (Review). [PDF]

Mol Med Rep
Qin Y, Zhou Y.
europepmc   +1 more source

Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia. [PDF]

Oncol Res
Tsubaki M, Matsuo T, Komori R.
europepmc   +1 more source

Non-receptor tyrosine kinase signaling pathways and therapeutic implications. [PDF]

Signal Transduct Target Ther
Hossain MDA, Marques Cuoco C, Sodaye SH, Beci J, Belkas K.   +4 more
europepmc   +1 more source

Bradyarrhythmias Associated with Oncologic Treatment-An Updated Review. [PDF]

Cancers (Basel)
Stępień J, Stępniak-Bielecka J, Ciołek A, Piotrowski J, Kryca A, Piotrowski G.   +5 more
europepmc   +1 more source

Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy. [PDF]

Oncologist
Cai J, Huang Z, Li Y, Zhou J, Xu Y, Cai M, Zhao H, Zhao B.   +7 more
europepmc   +1 more source

BCR::ABL1 tyrosine kinase inhibitors induce ribosome collisions to activate ZAK-dependent ribotoxic stress and apoptosis in chronic myeloid leukemia. [PDF]

Leukemia
Park J, Kim SH, Park J, Park H, Kim H, Kim DW, Lim C.   +6 more
europepmc   +1 more source

Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report. [PDF]

Ann Hematol
Wu M, Huang L, Yao Y, Xu Y, Yang Y, Luo J, Liu Z.   +6 more
europepmc   +1 more source

NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways. [PDF]

J Immunother Cancer
To A, Sugimura R.
europepmc   +1 more source

Screening of kinase inhibitors in the triple negative KRAS G13D-mutated MDA-MB-231 breast cancer cell line. [PDF]

Sci Rep
Stickler S, Eggerstorfer MT, Rieche M, Arslan S, Teufelsbauer M, Hohenegger M, Weigl L, Hamilton G.   +7 more
europepmc   +1 more source